SIRPA and ovarian cancer: Compared to control, CD47 blockade with SIRPa-Fc decoy receptor (TTI-621) enhanced macrophage-mediated in-vitro phagocytosis of ovarian cancer cells (OVCAR3 and TOV-21G) (Fig. 2A and Supplementary Fig. 4).